To improve the efficiency of the European healthcare system, the innovative CLEWICU solution identifies patients with an increased likelihood of being diagnosed with respiratory failure or hemodynamic instability, prioritizes workflow and treatment, and optimizes the allocation of critical care resources

The highly experienced healthcare executives will advise CLEW Medical as the company expands its product offering in North America following FDA 510k approval

CLEWICU is the industry’s first-ever cleared device for predicting the likelihood of patient deterioration up to 8 hours in advance based on hemodynamic instability, enabling earlier evaluation and subsequent care plans

CLEWICU is the only device authorized by the FDA to provide early identification of patients who are likely to experience respiratory failure or hemodynamic instability, both potentially common but significant complications associated with COVID-19

Relyens forges five exclusive technology partnerships to enhance the operational safety of healthcare professionals and local authorities

Funding will be used to scale US operations and commercialize CLEW’s critical care platform

Prominent healthcare technology pioneer to advise CLEW as the company expands its product offering across the entire continuum of care

Featuring healthcare industry experts, the program will show how critical care units are using AI-Machine Learning to deliver true patient value

CLEW used Google Compute Engine to build a reliable, scalable, cloud-based machine learning platform to develop and train its critical care algorithms.

The study will focus on the feasibility of using the Israeli startup’s analytics platform to predict patient deterioration from infection.

Israeli startup Intensix is developing analytics for early detection of complications or deterioration in intensive care patients.

Most Innovative startup at the 22nd annual conference of the Israeli Society for Quality in Healthcare for presenting “The Next Game Changer in Critical Care”